At a ceremony in Los Angeles, the Breakthrough Prize in Life Sciences was awarded to three researchers for developing a gene therapy that restores vision to patients with a rare inherited form of blindness.
Leber congenital amaurosis, caused by mutations in the RPE65 gene, disrupts the retina’s visual cycle and typically leads to severe vision loss before adulthood and total blindness shortly thereafter.
The therapy delivers a functional copy of the RPE65 gene to retinal cells using an adeno‑associated virus vector administered by subretinal injection, allowing the visual cycle to resume and enabling patients to perceive details previously invisible.
Work began in the early 1990s at the University of Pennsylvania, where the team refined the technique and first demonstrated restored sight in dogs bred with the same genetic defect.
In 2007, the first human patient—a 26‑year‑old woman—received the injection, marking the start of clinical development for the treatment.
After a decade of trials, the therapy received regulatory approval in December 2017 as the first gene‑replacement treatment for an inherited disease in the United States.
Recipients have reported dramatic improvements, such as seeing in low light and, in some cases, qualifying for driver’s licenses.
A collaborator helped bridge the gap between academic discovery and regulatory pathways, securing licensing agreements that expanded distribution to Europe as well as the United States.
The thirty‑year journey from laboratory research to an approved therapy illustrates the long horizon required for foundational biomedical advances.
The prize emphasizes recognition of work that advances fundamental knowledge without immediate commercial incentives, highlighting research that often falls outside typical funding cycles.
Other laureates honored at the same ceremony included scientists whose decades‑long investigations led to gene‑editing treatments for inherited blood disorders and to the identification of a common genetic cause of ALS and frontotemporal dementia.
These awards underscore the importance of sustained investment in basic science, which can ultimately produce life‑changing therapies for conditions affecting relatively small patient populations.
The recognition brings public attention to the cumulative effort needed to translate laboratory discoveries into treatments, reinforcing the value of long‑term scientific commitment.
